-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
The face of increasing incidence of inflammatory bowel disease, China handling these digestion tools and experience more tract disease to immune modulators (azathioprine - mercaptopurine), biologic or small molecule drug The representative drugs form the basis for the treatment of inflammatory bowel disease (IBD), Crohn's disease (CD) and ulcerative colitis (UC)
.
In the past three decades, the advent of such drugs has completely changed the ability of clinicians to treat IBD, reducing the number of diseases-related surgeries and hospitalizations
The face of increasing incidence of inflammatory bowel disease, China handling these digestion tools and experience more tract disease to immune modulators (azathioprine - mercaptopurine), biologic or small molecule drug The representative drugs form the basis for the treatment of inflammatory bowel disease (IBD), Crohn's disease (CD) and ulcerative colitis (UC)
Lymphoma and Ulcerative Colitis
This is a retrospective study of IBD patients with current or previous cancer history.
These patients were prescribed VDZ, tumor necrosis factor alpha antagonist (anti-TNF therapy), or did not receive immunosuppressive therapy after cancer diagnosis
.
During the follow-up, the occurrence of new primary cancer or recurrent cancer was determined
diagnosis
The study included a total of 96 patients who were treated with VDZ after a previous cancer diagnosis.
The researchers then compared the outcomes of 184 and 183 patients who were exposed to anti-TNF or who did not receive immunosuppressive therapy
.
The most common primary cancer is a solid tumor (50%)
This study confirmed that in patients with previous malignancies, vedolizumab and TNF antagonists are not associated with an increased risk of new or recurring cancer
.
.
Original source:
Amar Vedamurthy.
Vedolizumab or Tumor Necrosis Factor Antagonist Use and Risk of New or Recurrent Cancer in Patients With Inflammatory Bowel Disease With Prior Malignancy: A Retrospective Cohort Study.
Leave a message here
